Mutant-selective EGFR inhibitors and uses thereof
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is —CF 3 or —Cl;
W is —O— or —NH—;
R 2 is —R or
R 3 is —R, —C(O)R, or —C(O)OR; and
each R is independently C 1-4 alkyl or C 1-4 fluoroalkyl.
2. The compound according to claim 1 , wherein R 1 is —CF 3 .
3. The compound according to claim 1 , wherein R 1 is —Cl.
4. The compound according to claim 1 , wherein R 2 is
5. A compound of formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R 3 is —R, —C(O)R, or —C(O)OR; and
each R is independently C 1-4 alkyl or C 1-4 fluoroalkyl.
6. The compound according to claim 1 , selected from:
or a pharmaceutically acceptable salt thereof.
7. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
8. The composition according to claim 7 , in combination with an additional therapeutic agent.
9. The composition according to claim 8 , wherein the additional therapeutic agent is a chemotherapeutic agent.